sales@fnfresearch.comTel: +91 96043 17127 | USA: 1 (347) 690-0211

Search Market Research Report

Home / Category / Healthcare / Cancer Gene Therapy

Cancer Gene Therapy Market By Type (Ex-vivo and In-vivo) and By Product (Viral Vectors, Non-viral Vectors, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026

  • Publish On: Mar-2020
  • Total Pages: 185
  • Report Code: FAF-898
  • Base Year: 2019
  • Format:

Industry Insights

This specialized and expertise oriented industry research report scrutinizes the technical and commercial business outlook of the Cancer gene therapy industry. The report analyzes and declares the historical and current trends analysis of the Cancer gene therapy industry and subsequently recommends the projected trends anticipated to be observed in the Cancer gene therapy market during the upcoming years.

The Cancer gene therapy market report analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire Cancer gene therapy market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Million) from FY 2016 – 2026.

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the Cancer gene therapy industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Throughout our research report, we have encompassed all the proven models and tools of industry analysis and extensively illustrated all the key business strategies and business models adopted in the Cancer gene therapy industry. The report provides an all-inclusive and detailed competitive landscape prevalent in the Cancer gene therapy market.

The report utilizes established industry analysis tools and models such as Porter’s Five Forces framework to analyze and recognize critical business strategies adopted by various stakeholders involved in the entire value chain of the Cancer gene therapy industry. The Cancer gene therapy market report additionally employs SWOT analysis and PESTLE analysis models for further in-depth analysis.

The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the Cancer gene therapy sector. Key strategic developments in the Cancer gene therapy market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the Cancer gene therapy market are appropriately highlighted in the report.

The cancer gene therapy market was accounted for approximately USD 800 million in 2019. The market is projected to grow at a CAGR of 23% and is anticipated to reach around USD 3,400 million by 2026.

A growing number of cancer patients and increasing geriatric population base are important factors contributing to the growth of the world market in cancer gene therapy. Every year there is an increase in cancer patients worldwide. Cancer is the second leading cause of death in 2016, according to the WHO. It is also believed that one in six deaths was caused by cancer. Another important factor in the prevalence of cancer gene therapy is the increase in R&D activities, owing to significant investments in cancer gene therapy.

The Cancer gene therapy market research report delivers an acute valuation and taxonomy of the Cancer gene therapy industry by practically splitting the market on the basis of different types, applications, and regions. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The regional segmentation of the Cancer gene therapy industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Further, country-wise data for the Cancer gene therapy industry is provided for the leading economies of the world.

The Cancer gene therapy market is segmented based on Type, product and end-user. On the basis of type segmentation, the market is classified into Ex-vivo and In-vivo. In terms of product segmentation, the market is bifurcated into Viral Vectors, Non-viral Vectors, and Others. By End-User, the market is divided into Biopharma companies, Research institutes, and Others.

Some of the essential players operating in the Cancer gene therapy market, but not restricted to include Vigene Biosciences, Sirion Biotech, Bluebird bio, Cellectis, Ziopharm, Cobra, Uniqure, Finvector, Sarepta Therapeutics, and others.

The taxonomy of the Cancer gene therapy industry by its scope and segmentation is as follows:

Global Cancer gene therapy Market: By Type Segmentation Analysis (Customizable)

  • Ex-vivo
  • In-vivo

Global Cancer gene therapy Market: By Product Segmentation Analysis (Customizable)

  • Viral Vectors
  • Non-viral Vectors
  • Others

Global Cancer gene therapy Market: By End-Use Segmentation Analysis (Customizable)

  • Biopharma companies
  • Research institutes
  • Others

Global Cancer gene therapy Market: Regional Segmentation Analysis (Customizable)

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • The UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

KEY REPORT POINTERS & HIGHLIGHTS:

  • Statistically Validated Analysis of Historical, Current, and Projected Industry Trends with Authenticated Market Sizes Information and Data in terms of Value and Volume, wherever applicable
  • Direct and Indirect Factors that Impacted the Industry as well Projected Rationales expected to affect the industry going forward
  • Micro, Meso, Macro, and In-Depth Analysis of Technically relevant and Commercially viable Segments and Sub-segments of the Market
  • Historical and Projected Company / Vendor / OEM / Supplier Market Shares, Competitive Landscape, and Player Positioning Data
  • Historical and Current Demand (Consumption) and Supply (Production) Scenarios as well as Projected Supply-Demand Scenario Analysis
  • Detailed List of Key Buyers and End-Users (Consumers) analyzed as per Regions and Applications
  • Value Chain and Supply Chain Analysis along with Horizontal and Vertical Integration Scenarios
  • Manufacturing and Production Cost Structure Analysis including Labor Cost, Raw Material Expenses, and Other Manufacturing Expenses, wherever relevant
  • Overview of Key Marketing Strategies and Key Sales Channels Adopted in the Market
  • Market Attractiveness Analysis and Key Investment Opportunity Analysis in the Market going forward
  • Technological Roadmap, Patents Analysis, Potential Substitutes, and Technical Analysis
  • The professionally substantiated market research report study is calculated, constructed, and assembled by implementing a Robust Research Methodology. The Triangular Process comprises a buoyant mix of Exhaustive Primary Research (focused interviews, questionnaires, and ad-hoc surveys) and Extended Secondary Research (paid external databases, proprietary in-house database, and publically-available validated sources), where it is finally triangulated and validated through in-house industry experts, industry leaders, and independent consultants through a tri-level quality check practice.

Table of Content

  1. CHAPTER 1. Executive Summary
  2. CHAPTER 2. Cancer gene therapy market – Type Analysis
    1. 2.1. Global Cancer gene therapy Market – Type Overview
    2. 2.2. Global Cancer gene therapy Market Share, by Type, 2019 & 2026 (USD Million)
    3. 2.3. Ex-vivo
      1. 2.3.1. Global Ex-vivo Cancer gene therapy Market, 2016-2026 (USD Million)
    4. 2.4. In-vivo
      1. 2.4.1. Global In-vivo Cancer gene therapy Market, 2016-2026 (USD Million)
  3. CHAPTER 3. Cancer gene therapy market – Product Analysis
    1. 3.1. Global Cancer gene therapy Market – Product Overview
    2. 3.2. Global Cancer gene therapy Market Share, by Product, 2019 & 2026 (USD Million)
    3. 3.3. Viral Vectors
      1. 3.3.1. Global Viral Vectors Cancer gene therapy Market, 2016-2026 (USD Million)
    4. 3.4. Non-viral Vectors
      1. 3.4.1. Global Non-viral Vectors Cancer gene therapy Market, 2016-2026 (USD Million)
    5. 3.5. Others
      1. 3.5.1. Global Others Cancer gene therapy Market, 2016-2026 (USD Million)
  4. CHAPTER 4. Cancer gene therapy market – End-use Analysis
    1. 4.1. Global Cancer gene therapy Market – End-use Overview
    2. 4.2. Global Cancer gene therapy Market Share, by End-use, 2019 & 2026 (USD Million)
    3. 4.3. Biopharma companies
      1. 4.3.1. Global Biopharma companies Cancer gene therapy Market, 2016-2026 (USD Million)
    4. 4.4. Research institutes
      1. 4.4.1. Global Research institutes Cancer gene therapy Market, 2016-2026 (USD Million)
    5. 4.5. Others
      1. 4.5.1. Global Others Cancer gene therapy Market, 2016-2026 (USD Million)
  5. CHAPTER 5. Cancer gene therapy market – Regional Analysis
    1. 5.1. Global Cancer gene therapy Market Regional Overview
    2. 5.2. Global Cancer gene therapy Market Share, by Region, 2019 & 2026 (Value)
    3. 5.3. North America
      1. 5.3.1. North America Cancer gene therapy Market size and forecast, 2016-2026
      2. 5.3.2. North America Cancer gene therapy Market, by Country, 2019 & 2026 (USD Million)
      3. 5.3.3. North America Cancer gene therapy Market, by Type, 2016-2026
        1. 5.3.3.1. North America Cancer gene therapy Market, by Type, 2016-2026 (USD Million)
      4. 5.3.4. North America Cancer gene therapy Market, by Product, 2016-2026
        1. 5.3.4.1. North America Cancer gene therapy Market, by Product, 2016-2026 (USD Million)
      5. 5.3.5. North America Cancer gene therapy Market, by End-use, 2016-2026
        1. 5.3.5.1. North America Cancer gene therapy Market, by End-use, 2016-2026 (USD Million)
      6. 5.3.6. U.S.
        1. 5.3.6.1. U.S. Market size and forecast, 2016-2026 (USD Million)
      7. 5.3.7. Canada
        1. 5.3.7.1. Canada Market size and forecast, 2016-2026 (USD Million)
    4. 5.4. Europe
      1. 5.4.1. Europe Cancer gene therapy Market size and forecast, 2016-2026
      2. 5.4.2. Europe Cancer gene therapy Market, by Country, 2019 & 2026 (USD Million)
      3. 5.4.3. Europe Cancer gene therapy Market, by Type, 2016-2026
        1. 5.4.3.1. Europe Cancer gene therapy Market, by Type, 2016-2026 (USD Million)
      4. 5.4.4. Europe Cancer gene therapy Market, by Product, 2016-2026
        1. 5.4.4.1. Europe Cancer gene therapy Market, by Product, 2016-2026 (USD Million)
      5. 5.4.5. Europe Cancer gene therapy Market, by End-use, 2016-2026
        1. 5.4.5.1. Europe Cancer gene therapy Market, by End-use, 2016-2026 (USD Million)
      6. 5.4.6. Germany
        1. 5.4.6.1. Germany Market size and forecast, 2016-2026 (USD Million)
      7. 5.4.7. France
        1. 5.4.7.1. France Market size and forecast, 2016-2026 (USD Million)
      8. 5.4.8. U.K.
        1. 5.4.8.1. U.K. Market size and forecast, 2016-2026 (USD Million)
      9. 5.4.9. Italy
        1. 5.4.9.1. Italy Market size and forecast, 2016-2026 (USD Million)
      10. 5.4.10. Spain
        1. 5.4.10.1. Spain Market size and forecast, 2016-2026 (USD Million)
      11. 5.4.11. Rest of Europe
        1. 5.4.11.1. Rest of Europe Market size and forecast, 2016-2026 (USD Million)
    5. 5.5. Asia Pacific
      1. 5.5.1. Asia Pacific Cancer gene therapy Market size and forecast, 2016-2026
      2. 5.5.2. Asia Pacific Cancer gene therapy Market, by Country, 2019 & 2026 (USD Million)
      3. 5.5.3. Asia Pacific Cancer gene therapy Market, by Type, 2016-2026
        1. 5.5.3.1. Asia Pacific Cancer gene therapy Market, by Type, 2016-2026 (USD Million)
      4. 5.5.4. Asia Pacific Cancer gene therapy Market, by Product, 2016-2026
        1. 5.5.4.1. Asia Pacific Cancer gene therapy Market, by Product, 2016-2026 (USD Million)
      5. 5.5.5. Asia Pacific Cancer gene therapy Market, by End-use, 2016-2026
        1. 5.5.5.1. Asia Pacific Cancer gene therapy Market, by End-use, 2016-2026 (USD Million)
      6. 5.5.6. China
        1. 5.5.6.1. China Market size and forecast, 2016-2026 (USD Million)
      7. 5.5.7. Japan
        1. 5.5.7.1. Japan Market size and forecast, 2016-2026 (USD Million)
      8. 5.5.8. India
        1. 5.5.8.1. India Market size and forecast, 2016-2026 (USD Million)
      9. 5.5.9. South Korea
        1. 5.5.9.1. South Korea Market size and forecast, 2016-2026 (USD Million)
      10. 5.5.10. South-East Asia
        1. 5.5.10.1. South-East Asia Market size and forecast, 2016-2026 (USD Million)
      11. 5.5.11. Rest of Asia Pacific
        1. 5.5.11.1. Rest of Asia Pacific Market size and forecast, 2016-2026 (USD Million)
    6. 5.6. Latin America
      1. 5.6.1. Latin America Cancer gene therapy Market size and forecast, 2016-2026
      2. 5.6.2. Latin America Cancer gene therapy Market, by Country, 2019 & 2026 (USD Million)
      3. 5.6.3. Latin America Cancer gene therapy Market, by Type, 2016-2026
        1. 5.6.3.1. Latin America Cancer gene therapy Market, by Type, 2016-2026 (USD Million)
      4. 5.6.4. Latin America Cancer gene therapy Market, by Product, 2016-2026
        1. 5.6.4.1. Latin America Cancer gene therapy Market, by Product, 2016-2026 (USD Million)
      5. 5.6.5. Latin America Cancer gene therapy Market, by End-use, 2016-2026
        1. 5.6.5.1. Latin America Cancer gene therapy Market, by End-use, 2016-2026 (USD Million)
      6. 5.6.6. Brazil
        1. 5.6.6.1. Brazil Market size and forecast, 2016-2026 (USD Million)
      7. 5.6.7. Mexico
        1. 5.6.7.1. Mexico Market size and forecast, 2016-2026 (USD Million)
      8. 5.6.8. Rest of Latin America
        1. 5.6.8.1. Rest of Latin America Market size and forecast, 2016-2026 (USD Million)
    7. 5.7. The Middle-East and Africa
      1. 5.7.1. The Middle-East and Africa Cancer gene therapy Market size and forecast, 2016-2026
      2. 5.7.2. The Middle-East and Africa Cancer gene therapy Market, by Country, 2019 & 2026 (USD Million)
      3. 5.7.3. The Middle-East and Africa Cancer gene therapy Market, by Type, 2016-2026
        1. 5.7.3.1. The Middle-East and Africa Cancer gene therapy Market, by Type, 2016-2026 (USD Million)
      4. 5.7.4. The Middle-East and Africa Cancer gene therapy Market, by Product, 2016-2026
        1. 5.7.4.1. The Middle-East and Africa Cancer gene therapy Market, by Product, 2016-2026 (USD Million)
      5. 5.7.5. The Middle-East and Africa Cancer gene therapy Market, by End-use, 2016-2026
        1. 5.7.5.1. The Middle-East and Africa Cancer gene therapy Market, by End-use, 2016-2026 (USD Million)
      6. 5.7.6. GCC Countries
        1. 5.7.6.1. GCC Countries Market size and forecast, 2016-2026 (USD Million)
      7. 5.7.7. South Africa
        1. 5.7.7.1. South Africa Market size and forecast, 2016-2026 (USD Million)
      8. 5.7.8. Rest of Middle-East Africa
        1. 5.7.8.1. Rest of Middle-East Africa Market size and forecast, 2016-2026 (USD Million)
  6. CHAPTER 6. Cancer gene therapy market – Competitive Landscape
    1. 6.1. Competitor Market Share – Revenue
    2. 6.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    3. 6.3. Strategic Development
      1. 6.3.1. Acquisitions and Mergers
      2. 6.3.2. New Products
      3. 6.3.3. Research & Development Activities
  7. CHAPTER 7. Company Profiles
    1. 7.1. Vigene Biosciences
      1. 7.1.1. Company Overview
      2. 7.1.2. Vigene Biosciences Revenue and Gross Margin
      3. 7.1.3. Product portfolio
      4. 7.1.4. Recent initiatives
    2. 7.2. Sirion Biotech
      1. 7.2.1. Company Overview
      2. 7.2.2. Sirion Biotech Revenue and Gross Margin
      3. 7.2.3. Product portfolio
      4. 7.2.4. Recent initiatives
    3. 7.3. Bluebird bio
      1. 7.3.1. Company Overview
      2. 7.3.2. Bluebird bio Revenue and Gross Margin
      3. 7.3.3. Product portfolio
      4. 7.3.4. Recent initiatives
    4. 7.4. Cellectis
      1. 7.4.1. Company Overview
      2. 7.4.2. Cellectis Revenue and Gross Margin
      3. 7.4.3. Product portfolio
      4. 7.4.4. Recent initiatives
    5. 7.5. Ziopharm
      1. 7.5.1. Company Overview
      2. 7.5.2. Ziopharm Revenue and Gross Margin
      3. 7.5.3. Product portfolio
      4. 7.5.4. Recent initiatives
    6. 7.6. Cobra
      1. 7.6.1. Company Overview
      2. 7.6.2. Cobra Revenue and Gross Margin
      3. 7.6.3. Product portfolio
      4. 7.6.4. Recent initiatives
    7. 7.7. Uniqure
      1. 7.7.1. Company Overview
      2. 7.7.2. Uniqure Revenue and Gross Margin
      3. 7.7.3. Product portfolio
      4. 7.7.4. Recent initiatives
    8. 7.8. Finvector
      1. 7.8.1. Company Overview
      2. 7.8.2. Finvector Revenue and Gross Margin
      3. 7.8.3. Product portfolio
      4. 7.8.4. Recent initiatives
    9. 7.9. Sarepta Therapeutics
      1. 7.9.1. Company Overview
      2. 7.9.2. Sarepta Therapeutics Revenue and Gross Margin
      3. 7.9.3. Product portfolio
      4. 7.9.4. Recent initiatives
  8. CHAPTER 8. Cancer gene therapy — Industry Analysis
    1. 8.1. Cancer gene therapy Market – Key Trends
      1. 8.1.1. Market Drivers
      2. 8.1.2. Market Restraints
      3. 8.1.3. Market Opportunities
    2. 8.2. Value Chain Analysis
    3. 8.3. Technology Roadmap and Timeline
    4. 8.4. Cancer gene therapy Market – Attractiveness Analysis
      1. 8.4.1. By Type
      2. 8.4.2. By Product
      3. 8.4.3. By End-use
      4. 8.4.4. By Region
  9. CHAPTER 9. Marketing Strategy Analysis, Distributors
    1. 9.1. Marketing Channel
    2. 9.2. Direct Marketing
    3. 9.3. Indirect Marketing
    4. 9.4. Marketing Channel Development Trend
    5. 9.5. Economic/Political Environmental Change
  10. CHAPTER 10. Report Conclusion
  11. CHAPTER 11. Research Approach & Methodology
    1. 11.1. Report Description
    2. 11.2. Research Scope
    3. 11.3. Research Methodology
      1. 11.3.1. Secondary Research
      2. 11.3.2. Primary Research
      3. 11.3.3. Models
        1. 11.3.3.1. Company Share Analysis Model
        2. 11.3.3.2. Revenue Based Modeling
        3. 11.3.3.3. Research Limitations

        List of Figures

        FIG. 1 Global Cancer gene therapy Market, 2016-2026 (USD Million)
        FIG. 2 Global Cancer gene therapy Market Share, by Type, 2019 & 2026 (USD Million)
        FIG. 3 Global Ex-vivo Cancer gene therapy Market, 2016-2026 (USD Million)
        FIG. 4 Global In-vivo Cancer gene therapy Market, 2016-2026 (USD Million)
        FIG. 5 Global Cancer gene therapy Market Share, by Product, 2019 & 2026 (USD Million)
        FIG. 6 Global Viral Vectors Cancer gene therapy Market, 2016-2026 (USD Million)
        FIG. 7 Global Non-viral Vectors Cancer gene therapy Market, 2016-2026 (USD Million)
        FIG. 8 Global Others Cancer gene therapy Market, 2016-2026 (USD Million)
        FIG. 9 Global Cancer gene therapy Market Share, by End-use, 2019 & 2026 (USD Million)
        FIG. 10 Global Biopharma companies Cancer gene therapy Market, 2016-2026 (USD Million)
        FIG. 11 Global Research institutes Cancer gene therapy Market, 2016-2026 (USD Million)
        FIG. 12 Global Others Cancer gene therapy Market, 2016-2026 (USD Million)
        FIG. 13 Global Cancer gene therapy Market Share, by Region, 2019 & 2026
        FIG. 14 North America Cancer gene therapy Market, 2016-2026
        FIG. 15 U.S. Cancer gene therapy Market, 2016-2026
        FIG. 16 Canada Cancer gene therapy Market, 2016-2026
        FIG. 17 Europe Cancer gene therapy Market, 2016-2026
        FIG. 18 Germany Cancer gene therapy Market, 2016-2026
        FIG. 19 France Cancer gene therapy Market, 2016-2026
        FIG. 20 U.K. Cancer gene therapy Market, 2016-2026
        FIG. 21 Italy Cancer gene therapy Market, 2016-2026
        FIG. 22 Spain Cancer gene therapy Market, 2016-2026
        FIG. 23 Rest of Europe Cancer gene therapy Market, 2016-2026
        FIG. 24 Asia Pacific Cancer gene therapy Market, 2016-2026
        FIG. 25 China Cancer gene therapy Market, 2016-2026
        FIG. 26 Japan Cancer gene therapy Market, 2016-2026
        FIG. 27 India Cancer gene therapy Market, 2016-2026
        FIG. 28 South  Korea Cancer gene therapy Market, 2016-2026
        FIG. 29 South-East Asia Cancer gene therapy Market, 2016-2026
        FIG. 30 Rest of Asia Pacific Cancer gene therapy Market, 2016-2026
        FIG. 31 Latin America Cancer gene therapy Market, 2016-2026
        FIG. 32 Brazil Cancer gene therapy Market, 2016-2026
        FIG. 33 Mexico Cancer gene therapy Market, 2016-2026
        FIG. 34 Rest of Latin America Cancer gene therapy Market, 2016-2026
        FIG. 35 The Middle-East and Africa Cancer gene therapy Market, 2016-2026
        FIG. 36 GCC Countries Cancer gene therapy Market, 2016-2026
        FIG. 37 South Africa Cancer gene therapy Market, 2016-2026
        FIG. 38 Rest of Middle-East Africa Cancer gene therapy Market, 2016-2026
        FIG. 39 Competitor Market Share – Revenue
        FIG. 40 Vigene Biosciences Revenue and Growth Rate
        FIG. 41 Vigene Biosciences Market Share
        FIG. 42 Sirion Biotech Revenue and Growth Rate
        FIG. 43 Sirion Biotech Market Share
        FIG. 44 Bluebird bio Revenue and Growth Rate
        FIG. 45 Bluebird bio Market Share
        FIG. 46 Cellectis Revenue and Growth Rate
        FIG. 47 Cellectis Market Share
        FIG. 48 Ziopharm Revenue and Growth Rate
        FIG. 49 Ziopharm Market Share
        FIG. 50 Cobra Revenue and Growth Rate
        FIG. 51 Cobra Market Share
        FIG. 52 Uniqure Revenue and Growth Rate
        FIG. 53 Uniqure Market Share
        FIG. 54 Finvector Revenue and Growth Rate
        FIG. 55 Finvector Market Share
        FIG. 56 Sarepta Therapeutics Revenue and Growth Rate
        FIG. 57 Sarepta Therapeutics Market Share
        FIG. 58 Market Dynamics
        FIG. 59 Global Cancer gene therapy – Value Chain Analysis
        FIG. 60 Technology Roadmap and Timeline
        FIG. 61 Market Attractiveness Analysis – By Type
        FIG. 62 Market Attractiveness Analysis – By Product
        FIG. 63 Market Attractiveness Analysis – By End-use
        FIG. 64 Market Attractiveness Analysis – By Region
        FIG. 65 Market Channel
        FIG. 66 Marketing Channel Development Trend
        FIG. 67 Growth in World Gross Product, 2008-2019

        List of Tables

        TABLE 1 Global Cancer gene therapy Market, 2019 & 2026 (USD Million)
        TABLE 2 Global Cancer gene therapy market, by Type, 2016-2026 (USD Million)
        TABLE 3 Global Cancer gene therapy market, by Product, 2016-2026 (USD Million)
        TABLE 4 Global Cancer gene therapy market, by End-use, 2016-2026 (USD Million)
        TABLE 5 Global Cancer gene therapy market, by Region, 2016-2026 (USD Million)
        TABLE 6 North America Cancer gene therapy Market, by Type, 2016-2026 (USD Million)
        TABLE 7 North America Cancer gene therapy Market, by Product, 2016-2026 (USD Million)
        TABLE 8 North America Cancer gene therapy Market, by End-use, 2016-2026 (USD Million)
        TABLE 9 Europe Cancer gene therapy Market, by Type, 2016-2026 (USD Million)
        TABLE 10 Europe Cancer gene therapy Market, by Product, 2016-2026 (USD Million)
        TABLE 11 Europe Cancer gene therapy Market, by End-use, 2016-2026 (USD Million)
        TABLE 12 Asia Pacific Cancer gene therapy Market, by Type, 2016-2026 (USD Million)
        TABLE 13 Asia Pacific Cancer gene therapy Market, by Product, 2016-2026 (USD Million)
        TABLE 14 Asia Pacific Cancer gene therapy Market, by End-use, 2016-2026 (USD Million)
        TABLE 15 Latin America Cancer gene therapy Market, by Type, 2016-2026 (USD Million)
        TABLE 16 Latin America Cancer gene therapy Market, by Product, 2016-2026 (USD Million)
        TABLE 17 Latin America Cancer gene therapy Market, by End-use, 2016-2026 (USD Million)
        TABLE 18 The Middle-East and Africa Cancer gene therapy Market, by Type, 2016-2026 (USD Million)
        TABLE 19 The Middle-East and Africa Cancer gene therapy Market, by Product, 2016-2026 (USD Million)
        TABLE 20 The Middle-East and Africa Cancer gene therapy Market, by End-use, 2016-2026 (USD Million)
        TABLE 21 Global Cancer gene therapy Market - Company Revenue Analysis 2016-2019 (USD Million)
        TABLE 22 Global Cancer gene therapy Market - Company Revenue Share Analysis 2016-2019(%)
        TABLE 23 Acquisitions and Mergers
        TABLE 24 New Product/Service Launch
        TABLE 25 Research & Development Activities
        TABLE 26 Market Drivers
        TABLE 27 Market Restraints
        TABLE 28 Market Opportunities
        

Key Insights from Primary Research

  • As per our primary respondents, the Cancer gene therapy market is set to grow annually at a rate of around 23%.
  • It was established through primary research that the Cancer gene therapy market was valued at around USD 800 million in 2019.
  • After secondary research, we performed face to face interviews to validate our data. The insights interviewee’s declared that Ex-vivo is the most used type for the global cancer gene therapy market.
  • On the basis of the product, the Non-viral Vectors segment dominated the global cancer gene therapy market in 2019. It accounted for around 47% share of the total market in 2019.
  • The Biopharma companies segment, on the basis of end-use segmentation, was the leading revenue-generating category accounting for around 59% share, in 2019.

Key Recommendations from Analysts

  • Based on the exhaustive secondary research done by our team, the Ex-vivo type is anticipated to become the most demanding type in the upcoming years, owing to the growing demand for Cancer gene therapy from the medical industry.
  • As per our analysts, North America recorded the highest market share of more than 39% by 2026, and the market is expected to bolster in this region, resulting in creating lucrative opportunities for new players.
  • Growing at a CAGR around 23%, the Cancer gene therapy market provides numerous opportunities for all of the involved stakeholders across the entire value chain.
  • Our analysts have identified Ex-vivo and Non-viral Vectors categories as the leading investment pockets for the Cancer gene therapymarket in terms of type and application segmentation respectively.
  • Our analysts recommend the emerging players to focus on Research institutes owing to the substantial growth of the pharmaceutical and medical industry worldwide.

Market Attractiveness – By Type

Cancer gene therapy Market

Industry Major Market Players

  •  Vigene Biosciences
  •  Sirion Biotech
  •  Bluebird bio
  •  Cellectis
  •  Ziopharm
  •  Cobra
  •  Uniqure
  •  Finvector
  •  Sarepta Therapeutics

Safe and Secure SSL Encrypted

Choose License Type

Inquiry For Buying

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

have a question

HAVE A QUESTION? Executive will help you find what you are looking for.


REQUEST CUSTOMIZATION

Still haven't found what you're looking for? Speak to our Custom Research Team

Learn More
Facts & Factors provides an array of marketing and business research solutions distinctly designed by our expertise for the clients.
Copyright © 2021 Facts & Factors. All Rights Reserved. Sitemap - Privacy Policy - Terms & Conditions